Captabine 500 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Capecitabine |
| Company | Techno drugs ltd |
| Also available as |
Indications
- Adjuvant Colon Cancer: Patients with Dukes'C colon cancer.
- Metastatic Colorectal Cancer: First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred.
- Metastatic Breast Cancer: In combination with docetaxel after failure of prior anthracycline containing therapy.
- Monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen.
Pharmacology
Capecitabine is a prodrug enzymatically converted to fluorouracil in the tumor, where it inhibits DNA synthesis and slows tumor growth.
Dosage & Administration
Monotherapy: 1250 mg/m2 twice daily orally for 2 weeks followed by a one-week rest period in 3-week cycles. Adjuvant treatment is recommended for a total of 6 months (8 cycles). In combination with docetaxel, the recommended dose of Capecitabine is 1250 mg/m2 twice daily for 2 weeks followed by a 7-day rest period, combined with docetaxel at 75 mg/m2 as a 1-hour IV infusion every 3 weeks.
Interaction
- Anticoagulants: Monitor anticoagulant response frequently.
- Phenytoin: Monitor phenytoin levels in patients taking Captabine concomitantly with phenytoin.
- Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
- CYP2C9 substrates: Care should be exercised when Captabine is co-administered with CYP2C9 substrates.
- Food: Reduces both the rate and extent of absorption of Captabine.
Contraindications
- Severe Renal Impairment
- Hypersensitivity
- Leucopenia, neutropenia, or thrombocytopenia
- Severe reactions to fluoropyrimidine therapy
- Complete DPD deficiency
- Pregnant or breast-feeding
Side Effects
- Abdominal pain
- Rash
- Tiredness
- Loss of appetite (anorexia)
- Diarrhea
- Vomiting
- Nausea
- Fever
- Infection
- Chest pain
- Steven-Johnson syndrome
Pregnancy & Lactation
Pregnancy category D. Capecitabine can cause fetal harm. Breast-feeding should be discontinued while receiving treatment with Capecitabine and for 2 weeks after the final dose.
Precautions & Warnings
- Coagulopathy: Monitor anticoagulant response frequently to avoid bleeding.
- Diarrhea: Captabine treatment should be stopped immediately until diarrhea resolves.
- Cardiotoxicity: Common in patients with a prior history of coronary artery disease.
- Increased Risk of Severe or Fatal Adverse Reactions in Patients with Low or Absent Dihydropyrimidine Dehydrogenase (DPD) Activity: Captabine should be withhold or permanently discontinued in patients with evidence of acute early-onset or unusually severe toxicity.
- Dehydration and Renal Failure: Captabine treatment should be stopped until dehydration is corrected.
- Mucocutaneous and Dermatologic Toxicity: Severe mucocutaneous reactions, Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported.
- Hyperbilirubinemia: Captabine treatment should be interrupted immediately until the hyperbilirubinemia resolves or decreases in intensity.
- Hematologic: Patients should not be treated with neutrophil counts <1.5x109/L or thrombocyte counts <100x109/L.
Overdose Effects
The manifestations of acute overdose include nausea, vomiting, diarrhea, mucositis, gastrointestinal irritation and bleeding, and bone marrow depression.
Therapeutic Class
Cytotoxic Chemotherapy
Storage Conditions
Keep in a dry place and store below 30°C. Protect from light and keep out of the reach of children.